EyePoint Inc
EYPTHealthcare|Biotechnology|USA
$14.72
-0.12 (-0.81%)
Tangible Book
$2.76
Upcoming Data Readouts (4)
Aug 2026
Est. completion
P3Wet Age Related Macular Degeneration
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
NCT06668064n=400
Oct 2026
Est. completion
P3Wet Age Related Macular Degeneration
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
NCT06683742n=400
Oct 2027
Est. completion
P3Diabetic Macular Edema
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
NCT07449923n=240
Oct 2027
Est. completion
P3Diabetic Macular Edema
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
NCT07449936n=240